Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists

被引：11

作者：

Crabtree, Thomas S. J. ^{[1
,2
,3
]}

Adamson, Karen ^{[4
]}

Reid, Hazel ^{[4
]}

Barnes, Dennis ^{[5
]}

Sivappriyan, Siva ^{[5
]}

Bickerton, Alex ^{[6
]}

Gallen, Ian W. ^{[7
]}

Field, Benjamin C. T. ^{[8
,9
]}

Idris, Iskandar ^{[2
,3
]}

Ryder, Robert E. J. ^{[1
]}

机构：

[1] Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Birmingham, W Midlands, England

[2] Univ Nottingham, Sch Med, Nottingham, England

[3] Univ Hosp Derby & Burton NHS Trust, Royal Derby Hosp, Derby, England

[4] St Johns Hosp, Livingston, Scotland

[5] Maidstone & Tunbridge Wells NHS Trust, Royal Tunbridge Wells, Kent, England

[6] Yeovil Dist Hosp NHS Trust, Yeovil, England

[7] Royal Berkshire Hosp NHS Trust, Reading, Berks, England

[8] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, Surrey, England

[9] Surrey & Sussex Healthcare NHS Trust, Guildford, Surrey, England

来源：

DIABETES OBESITY & METABOLISM | 2022年 / 24卷 / 07期

关键词：

GLP-1; analogue; observational study; type; 2; diabetes; ONCE-WEEKLY SEMAGLUTIDE; OPEN-LABEL; DULAGLUTIDE; EFFICACY; SAFETY;

D O I：

10.1111/dom.14701

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.

引用

页码：1398 / 1401

页数：4

共 11 条

[1] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial [J].

Ahmann, Andrew J. ;

Capehorn, Matthew ;

Charpentier, Guillaume ;

Dotta, Francesco ;

Henkel, Elena ;

Lingvay, Ildiko ;

Holst, Anders G. ;

Annett, Miriam P. ;

Aroda, Vanita R. .

DIABETES CARE, 2018, 41 (02) :258-266

[2] Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) [J].

Frias, Juan P. ;

Bonora, Enzo ;

Nevarez Ruiz, Luis ;

Li, Ying G. ;

Yu, Zhuoxin ;

Milicevic, Zvonko ;

Malik, Raleigh ;

Bethel, M. Angelyn ;

Cox, David A. .

DIABETES CARE, 2021, 44 (03) :765-773

[3] Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic [J].

Hansen, Katrine B. ;

Svendstrup, Mathilde ;

Lund, Asger ;

Knop, Filip K. ;

Vilsboll, Tina ;

Vestergaard, Henrik .

DIABETIC MEDICINE, 2021, 38 (10)

[4] Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study [J].

Hepprich, Matthias ;

Zillig, Daniela ;

Florian-Reynoso, Manuel A. ;

Donath, Marc Y. ;

Rudofsky, Gottfried .

DIABETES THERAPY, 2021, 12 (03) :943-954

[5] Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study [J].

Lingvay, Ildiko ;

Kirk, Andreas R. ;

Lophaven, Soren ;

Wolden, Michael L. ;

Shubrook, Jay H. .

DIABETES THERAPY, 2021, 12 (03) :879-896

[6] Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial [J].

Pratley, Richard E. ;

Aroda, Vanita R. ;

Lingvay, Ildiko ;

Luedemann, Jorg ;

Andreassen, Camilla ;

Navarria, Andrea ;

Viljoen, Adie .

LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (04) :275-286

[7] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial [J].

Rubino, Domenica M. ;

Greenway, Frank L. ;

Khalid, Usman ;

O'Neil, Patrick M. ;

Rosenstock, Julio ;

Sorrig, Rasmus ;

Wadden, Thomas A. ;

Wizert, Alicja ;

Garvey, W. Timothy .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (02) :138-150

[8] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial [J].

Sorli, Christopher ;

Harashima, Shin-ichi ;

Tsoukas, George M. ;

Unger, Jeffrey ;

Karsbol, Julie Derving ;

Hansen, Thomas ;

Bain, Stephen C. .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04) :251-260

[9] Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population [J].

Visaria, Jay ;

Uzoigwe, Chioma ;

Swift, Caroline ;

Dang-Tan, Tam ;

Paprocki, Yurek ;

Willey, Vincent J. .

CLINICAL THERAPEUTICS, 2021, 43 (05) :808-821

[10] Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study [J].

Williams, David M. ;

Ruslan, Aliya M. ;

Khan, Rahim ;

Vijayasingam, Daneeshanan ;

Iqbal, Fizzah ;

Shaikh, Ayesha ;

Lim, Jia ;

Chudleigh, Richard ;

Peter, Rajesh ;

Udiawar, Maneesh ;

Bain, Stephen C. ;

Stephens, Jeffrey W. ;

Min, Thinzar .

DIABETES THERAPY, 2021, 12 (03) :801-811

← 1 2 →